Patterns of anticoagulation following bioprosthetic valve implantation: Observations from ANSWER

Journal of Heart Valve Disease

Volumn 21, Issue 1, 2012, Pages 78-87

  Brennan, J Matthew ^a   Alexander, Karen P ^a   Wallace, Amelie ^d   Hodges, Audra B ^a   Laschinger, John C ^b   Jones, Kent W ^c   O'Brien, Sean ^a   Webb, Laura E ^a   Dokholyan, Rachel S ^a   Peterson, Eric D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b St Joseph Medical Center   (United States)

^c LDS HOSPITAL   (United States)

^d LDS Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

AGED; ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; EPISTAXIS; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HEART VALVE BIOPROSTHESIS; HEART VALVE REPLACEMENT; HEMATURIA; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MITRAL VALVE REPLACEMENT; MORTALITY; MULTICENTER STUDY (TOPIC); PRESCRIPTION; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; BIOPROSTHESIS; BLOOD CLOTTING; DRUG EFFECT; DRUG MONITORING; HEART VALVE PROSTHESIS; METHODOLOGY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; RISK ASSESSMENT; STANDARD; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BIOPROSTHESIS; BLOOD COAGULATION; DRUG MONITORING; FEMALE; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MORTALITY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; RISK ADJUSTMENT; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84860350160     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Brown JM, O'Brien SM, Wu C, Sikora JA, Griffith BP, Gammie JS. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: Changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J Thorac Cardiovasc Surg 2009;137:82-90
2. Gammie JS, Sheng S, Griffith BP, et al. Trends in mitral valve surgery in the United States: Results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg 2009;87:1431-1437; discussion 1437-1439
3. Fradet GJ, Jamieson WR, Abel JG, et al. Clinical performance of biological and mechanical prostheses. Ann Thorac Surg 1995;60:S453-S458
4. Jamieson WR, Lemieux MD, Sullivan JA, Munro AI, Metras J, Cartier PC. Medtronic intact porcine bioprosthesis: 10 years' experience. Ann Thorac Surg 1998;66:S118-S121
5. Seguin JR, Grandmougin D, Folliguet T, Warembourg H, Laborde F, Chaptal PA. Long-term results with the Sorin Pericarbon valve in the aortic position: A multicenter study. J Heart Valve Dis 1998;7:278-282
6. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Developed in Collaboration With the Society of Cardiovascular Anesthesiologists: Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006;114:e84-e231
7. The Cardiothoracic Surgery Network VTC. Anticoagulation therapy after aortic tissue valve replacement. December 17. Available at: http://www.ctsnet. org/file/AnticoagulationSurveyFinalResultsSlidesPDF.pdf. Accessed December 17, 2009
8. Vaughan P, Waterworth PD. An audit of anticoagulation practice among UK cardiothoracic consultant surgeons following valve replacement/repair. J Heart Valve Dis 2005;14:576-582
9. Colli A, Verhoye JP, Heijmen R, et al. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur J Cardiothorac Surg 2008;33:531-536
10. Aramendi JI, Mestres CA. Antithrombotic therapy after bioprosthetic aortic valve replacement. Eur J Cardiothorac Surg 2008;33:529-530
11. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC, Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009;301:831-841
12. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA 2003;290:2685-2692
13. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: Results of the managing anticoagulation services trial. Am J Med 2002;113:42-51
14. Meijer K, Kim YK, Schulman S. Decreasing warfarin sensitivity during the first three months after heart valve surgery: Implications for dosing. Thromb Res 2010;125:224-229
15. Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995;25:1111-1119
16. Brueck M, Kramer W, Vogt P, et al. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardiothorac Surg 2007;32:108-112
17. Gherli T, Colli A, Fragnito C, et al. Comparing warfarin with aspirin after biological aortic valve replacement: A prospective study. Circulation 2004;110:496-500
18. Sundt TM, Zehr KJ, Dearani JA, et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg 2005;129:1024-1031
19. Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: Results of the WoA Epic pilot trial. J Heart Valve Dis 2007;16:667-671
20. Aramendi JI, Mestres CA, Martinez-León J, Campos V, Mu oz G, Navas C. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): Prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 2005;27:854-860
21. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816-1828
22. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:429S-456S
23. Sidhu P, O'Kane HO. Self-managed anticoagulation: Results from a two-year prospective randomized trial with heart valve patients. Ann Thorac Surg 2001;72:1523-1527
24. Connolly SJ, Ezekowitz MD, Yusuf S, et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151
25. Schulman S, Kearon C, Kakkar AK, et al., RECOVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-2352